Dagnaw Desalegn Yayeh, Tafesse Abenet, Tsehayneh Fikru, Asefa Hanna, Hagos Teklil, Tarekegn Getahun, Sime Koricho
Department of Internal medicine, College of Health Sciences, Arsi University, Asella, Ethiopia.
Department of Neurology, college of health sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Ethiop J Health Sci. 2024 Nov;34(6):477-484. doi: 10.4314/ejhs.v34i6.7.
Erectile dysfunction (ED) is one of the earliest chronic complications of diabetes, with a worldwide prevalence ranging from 35% to 90%. This study aimed to assess the current prevalence and related factors of ED in individuals with diabetes.
An institution-based cross-sectional study was conducted with 269 participants. A validated questionnaire, including the International Index of Erectile Function-5 (IIEF-5), was utilized. Statistical analyses included chi-square tests and logistic regression to calculate the odds ratio (OR) and 95% confidence interval (CI). The strength of the association was determined using odds ratio (OR) with a 95% CI.
The mean age of respondents was 54.45 ± 13.19 years, and the mean duration of diabetes was 12.89 ± 8.98 years. Among the 269 respondents, 243 (90.3%) experienced varying degrees of ED. Statistically significant positive associations were identified for patients with a longer duration of diabetes (adjusted OR [AOR]: 19.10CI: 2.35-155.31), microvascular complications (AOR: 6.75,CI:1.55-29.17), insulin therapy (AOR: 4.76,CI: 1.34-17.07), comorbidities (AOR: 8.77,CI: 3.06-25.17), and medications other than those for diabetes (AOR: 4.62,CI: 1.16-18.45). Notably, 82.2% had never discussed ED with their physicians.
The prevalence of ED among diabetic patients is alarmingly high. This study identified significant positive associations between ED and factors such as diabetes duration, microvascular complications, insulin therapy (with or without oral agents), comorbid conditions, and the use of non-diabetes medications. Therefore, screening, treatment, and addressing key determinants of erectile dysfunction should be integrated into diabetes care.
勃起功能障碍（ED）是糖尿病最早出现的慢性并发症之一，在全球范围内的患病率为35%至90%。本研究旨在评估糖尿病患者中ED的当前患病率及相关因素。
对269名参与者进行了一项基于机构的横断面研究。使用了一份经过验证的问卷，包括国际勃起功能指数-5（IIEF-5）。统计分析包括卡方检验和逻辑回归，以计算比值比（OR）和95%置信区间（CI）。使用比值比（OR）和95%CI确定关联强度。
受访者的平均年龄为54.45±13.19岁，糖尿病平均病程为12.89±8.98年。在269名受访者中，243人（90.3%）经历了不同程度的ED。糖尿病病程较长的患者（调整后的OR[AOR]：19.10，CI：2.35-155.31）、微血管并发症（AOR：6.75，CI：1.55-29.17）、胰岛素治疗（AOR：4.76，CI：1.34-17.07）、合并症（AOR：8.77，CI：3.06-25.17）以及糖尿病以外的药物治疗（AOR：4.62，CI：1.16-18.45）之间存在统计学上显著的正相关。值得注意的是，82.2%的人从未与医生讨论过ED。
糖尿病患者中ED的患病率高得惊人。本研究确定了ED与糖尿病病程、微血管并发症、胰岛素治疗（无论是否使用口服药物）、合并症以及非糖尿病药物使用等因素之间存在显著的正相关。因此，勃起功能障碍的筛查、治疗和关键决定因素的解决应纳入糖尿病护理中。
